Observational Study to evaluate the effect and safety of Selumetinib in Pediatric Patients with NF1-PNs

Trial Identifier: D1346R00016
Sponsor: AstraZeneca
Start Date: December 2023
Primary Completion Date: May 2027
Study Completion Date: May 2027

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
China, China Nanjing, China, China
China, Chongqing Chongqing, China
China, Gansu Lanzhou, Gansu, China
China, Guangdong Shenzhen, Guangdong, China
China, Guangxi Nanning, Guangxi, China
China, Guizhou Guiyang, Guizhou, China
China, Hebei Shijiazhuang, Hebei, China
China, Hubei Wuhan, Hubei, China
China, Jiangsu Nanjing, Jiangsu, China
China, Jiangsu Suzhou, Jiangsu, China
China, Jiangxi Nanchang, Jiangxi, China
China, Shandong Ji nan, Shandong, China
China, Shandong Jinan, Shandong, China
China, Shanghai Shanghai, China
China, Shanxi Taiyuan, Shanxi, China
China, Shanxi Xi an, Shanxi, China
China, Sichuan Chengdu, Sichuan, China
China, Tianjin Tianjin, China
China, Yunnan Kunming, Yunnan, China
China, Zhejiang Wenzhou, Zhejiang, China